Coherus to Webcast Interim Tagmokitug Data on October 28
Coherus Oncology will release interim clinical data for tagmokitug on October 28, 2026. The tagmokitug program is evaluating a cytolytic CCR8 antibody with toripalimab in multiple solid tumors. The company will host a webcast with key opinion leaders to discuss the results.
Coherus Oncology, a commercial-stage cancer company, plans to disclose interim results from tagmokitug studies on Oct. 28, 2026. The program pairs a selective cytolytic CCR8 antibody with toripalimab, its approved PD-1 inhibitor, across several advanced solid tumor types.
The Phase 1b/2a work includes head and neck squamous cell carcinoma, colorectal, gastric, gastroesophageal junction, esophageal adenocarcinoma, and esophageal squamous cell carcinoma. Management will host a webcast that afternoon with invited clinical experts to discuss the findings and context.
If the interim results are encouraging, they could shape how oncologists view CCR8-directed combinations for difficult solid tumors. Patients with limited treatment options may gain another potential study pathway, while investors and partners may reassess Coherus’s pipeline prospects. Conversely, unclear or negative data could temper enthusiasm and affect trial momentum. The webcast may also help clinicians and analysts interpret early signals before fuller data review.